Selvedge Venture — Full Portfolio
12 tracked investments · listed companies and verified rows first
Alcolase is a biotech company developing science-based solutions for people with alcohol intolerance, a genetic condition affecting hundreds of millions of people, particularly in East Asia.
BiotechConsumerWellness & FitnessCopenhagen, DK
Mikkel Precht(Founder)in
Co-investorsAda VenturesAntlerAntler AustraliaElmehøj VenturesDelphinus Venture Capital
.jpeg){kind=logo}
BIOS develops neural digital therapy technology to deliver treatments for neurological conditions.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesCambridge, GB
Oliver Armitage(Founder)inEmil Hewage(Founder/Director)in
Co-investorsFifty YearsHeuristic Capital PartnersKern Venture GroupThe Venture CollectiveY Combinator
MIT is an educational and research institution in Cambridge, Massachusetts, pursuing teaching, research, and innovation across science, engineering, and other fields.
BiotechEdTechCambridge, US
Co-investorsBeyond Earth VenturesFlagship PioneeringFoundersX VenturesJIMCOLair East LabsMassChallenge Mexico
Carbometrics is developing i-CAM, a continuous metabolic monitor for cardiopulmonary bypass and organ perfusion circuits used in medical procedures.
HardwareHealthtechMedical Devices
Co-investorsAda VenturesScience Creates Ventures
Exogene is a techbio startup using a generative AI and deep learning platform to discover novel, high-affinity TCR-based (T-cell receptor) therapies for treating solid tumors.
AI & Machine LearningBiotechDeep TechHealthtechOxford, GB
Federico Paoletti(CEO & Co-Founder)inAndrea Mambrini(CTO & Co-Founder)in
Co-investorsEntrepreneur FirstUnruly CapitalR42 Group
Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection.
BiotechDeep TechHardwareCambridge, US
Cullen Buie(Director)inPaulo Garcia(Executive Officer, Director, Promoter)inMichael Chiu(Director, Executive Officer)in
BoardPaxton Major(Director)inAnn DeWitt(Director)inPaul Wotton(Director)
Co-investorsBantam GroupHorizons VenturesMassVenturesTBD AngelsTelegraph Hill PartnersThe Engine Ventures+2 more
Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models.
AI & Machine LearningBiotechHealthtechMedical DevicesLondon, GB
Quin Wills(Founder/CSO)inJack O'Meara(Founding CEO)in
BoardChinwe UkomaduElaine SullivanEliot ForsterJack Castle
Co-investorsBackedBeast VenturesCoastCapEntrepreneur FirstExpaHoxton Ventures+6 more
Oxford Medical Products develops medical devices, drawing on a team of biotech entrepreneurs, material scientists, polymer chemists and medical device engineers.
BiotechDigital HealthHealthtechMedical DevicesOxford, GB
Co-investorsOxford Investment Opportunity Network (OION)Ada Ventures
The Royal Society of Chemistry is a professional membership organisation that connects the global chemistry community through partnerships, conferences, networks and publications.
BiotechClimate TechEdTechEnergyImpact & Social GoodMedia & EntertainmentLondon, GB
Thomas Graham(First President)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.